

UNC BIRCH SCHOLARS

Boggess

****Boggess KA**, Kay HH, Crapo JD, Moore WF, Suliman HB, Oury TD. Differential localization of placental extracellular superoxide dismutase as pregnancy progresses. *Am J Obstet Gynecol* 2000;183(1):199-205.

****Boggess KA**, Myers ER, Hamilton CD. Antepartum or postpartum isoniazid treatment of latent tuberculosis infection. *Obstet Gynecol* 2000;96(5 Pt 1):757-62.

Shelton SD, **Boggess KA, Murtha AP, Groff AO, Herbert WN. Repeated fetal betamethasone treatment and birth weight and head circumference. *Obstet Gynecol* 2001;97(2):301-4.

Shelton SD, **Boggess KA, Kirvan K, Sedor F, Herbert WN. Urinary interleukin-8 with asymptomatic bacteriuria in pregnancy. *Obstet Gynecol* 2001;97(4):583-6.

Whitecar PW, **Boggess KA, McMahon MJ, Thorp JM Jr, Taylor DD. Altered expression of TCR-CD3zeta induced by sera from women with preeclampsia. *Am J Obstet Gynecol* 2001;185(4):812-8.

Offenbacher S, Lieff S, **Boggess KA, Murtha AP, Madianos PN, Champagne CM, McKaig RG, Jared HL, Mauriello SM, Auten RL Jr, Herbert WN, Beck JD. Maternal periodontitis and prematurity. Part I: Obstetric outcome of prematurity and growth restriction. *Ann Periodontol* 2001;6(1):164-74.

Madianos PN, Lieff S, Murtha AP, **Boggess KA, Auten RL Jr, Beck JD, Offenbacher S. Maternal periodontitis and prematurity. Part II: Maternal infection and fetal exposure. *Ann Periodontol* 2001;6(1):175-82.

Shelton SD, **Boggess KA, Smith T, Herbert WN. Effect of betamethasone on maternal glucose. *J Maternal Fetal Neonatal Med* 2002;12(3):191-5.

****Boggess KA**, Lieff S, Murtha AP, Moss K, Beck J, Offenbacher S. Maternal periodontal disease is associated with an increased risk for preeclampsia. *Obstet Gynecol* 2003;101(2):227-31.

Apparao KB, Illera MJ, Beyler SA, Olson GE, Osteen KG, Corjay MH, **Boggess KA, Lessey BA. Regulated expression of osteopontin in the peri-implantation rabbit uterus. *Biol Reprod* 2003;68(5):1484-90.

Lam GL, Orton S, Whitecar P, **Boggess KA, Taylor D. Differential expression of TcR-CD3 zeta as evidence for altered immunoregulation in preeclamptic versus normotensive women. *Am J Obstet* 2003;189:843-7.

Lieff S, **Boggess KA**, Murtha AP, Jared H, Moss K, Beck J, Offenbacher S. The oral conditions and pregnancy study: Periodontal status of a cohort of pregnant women. *J Periodontol*, in press.

Brown

Aris RM, Ontjes DA, Buell HE, Blackwood AD, Lark RK, Caminiti M, **Brown SA, Renner JB, Chalermkulrat W, Lester GE. Abnormal bone turnover in cystic fibrosis adults. *Osteoporos Int* 2002;13(2):151-7.

****Brown SA**, Ontjes DA, Lester GE, Lark RK, Hensler MB, Blackwood AD, Caminiti MJ, Backlund DC, Aris RM. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. *Osteoporos Int* 2003;14(5):442-9.

Aaris RM, Ontjes DO, **Brown SA, Chalermkulrat W, Neuringer I, Lester GE. Carboxylated osteocalcin levels in cystic fibrosis. *Am J Respir Crit Care Med* 2003;168:1129.

Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, **Brown SA, Neuringer IP, Chalermkulart W, Ontjes DA. Efficacy of alendronate in cystic fibrosis adults with low bone density. *Am J Respir Crit Care Med* 2003 Oct 16 [Epub ahead of print].

Rosen CJ, **Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. Letter to the Editor in *N Engl J Med* 2003;348:1503-4.

Brown SA. Hyperparathyroidism. **Brown SA**. Padget's Disease. Thomas MJ and **Brown SA**. Hypothyroidism. In: Netter's Textbook of Internal Medicine. Runge M and Greganti A, eds. ICON publishers, 2003.

Aris RM, **Brown SA**, Ontjes DA. Osteoporosis, metabolic bone disease and endocrine abnormalities. In: Non-Neoplastic Advanced Lung Disease. Janet Maurer, book editor "Lung Biology in Health and Disease", C. Lenfant, series editor. April 2003, Volume 176, p.607-635.

Gourlay ML, **Brown SA. Clinical considerations in premenopausal osteoporosis. Accepted by Archives of Internal Medicine, April 2003.

Brown SA, Rosen CJ. Osteoporosis. *Med Clin N Am* 2003; 87(5):1039-63.

Craven

****Craven RJ**, Petes TD. The *Saccharomyces cerevisiae* suppressor of choline sensitivity (SCS2) gene is a multicopy suppressor of *mec1* telomeric silencing defects. *Genetics* 2001;158(1):145-54.

****Craven RJ**, Greenwell PW, Dominska M, Petes TD. Regulation of genome stability by TEL1 and MEC1, yeast homologs of the mammalian ATM and ATR genes. *Genetics* 2002;161(2):493-507.

Golubovskaya V, Beviglia L, Xu L, Earp HS, **Craven RJ, Cance W. Focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) synergistically suppress death receptor-mediated apoptosis in human breast cancer cells by activating Akt and Erk 1 and 2 signaling pathways. *J Biol Chem* 2002; 277(41):38978-87.

Meyer T, Xu L, Chang J, Liu ET, **Craven RJ, Cance WG. Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase. *Int J Cancer* 2003;104(2):139-46.

Beviglia L, Golubovskaya V, Xu L, Yang X, **Craven RJ, Cance WG. Focal adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment and apoptosis. *Biochem J* 2003;373(Pt 1):201-10.

Hand RA, Jia N, Bard M, **Craven RJ. *Saccharomyces cerevisiae* Dap1p, a novel DNA damage response protein related to the mammalian membrane-associated progesterone receptor. *Eukaryot Cell* 2003;2(2):306-17.

****Craven RJ**, Lightfoot H, Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. *Surg Oncol* 2003;12(1):39-49.

Yang XH, Hand RA, Livasy CA, Cance WG, **Craven RJ. Overexpression of the receptor tyrosine kinase Tie-1 intracellular domain in breast cancer. *Tumour Biol* 2993;24(2):61-9.;

Dees

****Dees C**, Graham M. New strategies for metastatic breast cancer (review of the article). *Oncology* 2000;14(5):642-644.

****Dees EC**, O'Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ, Grochow LB, Donehower RC, Fetting JH. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. *Cancer Invest* 2000;18(6):521-9.

****Dees EC**, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC. A phase I pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. *Clin Cancer Res* 2000;6(10):3885-94.

****Dees EC**, Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. *Semin Oncol* 2001;28(4):322-31.

Orlowski RZ, **Dees EC**. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. *Breast Cancer Res* 2003;5(1):1-7.

****Dees EC**, Rowinsky EK, Noe DA, O'Reilly S, Adjei AA, Elza-Brown K, Donehower RC. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. *Invest New Drugs* 2003;21(1):75-84.

Gordon-Larsen

****Gordon-Larsen P**, Adair LS, Popkin BM. Ethnic differences in physical activity and inactivity patterns and overweight status. *Obes Res* 2002;10(3):141-9.

****Gordon-Larsen P**, Adair LS, Popkin BM. The relationship of ethnicity, socioeconomic factors, and overweight in US adolescents. *Obes Res* 2003;11(1):121-9.

****Gordon-Larsen P**, Harris KM, Ward DS, Popkin BM. Acculturation and overweight-related behaviors among Hispanic immigrants to the US: the National Longitudinal Study of Adolescent Health. *Soc Sci Med* 2003;57(11):2003-34.

Hartmann

****Windsor R**, Oncken C, Henningfield J, **Hartmann K**, Edwards N. Behaviors and pharmacological treatment methods for pregnant smokers: issues for clinical practice. *J Am Med Womens Assoc* 2000;55(5):304-10.

****Hartmann KE**, Barrett KE, Reid VC, McMahon MJ, Miller WC. Clinical usefulness of white blood cell count after cesarean delivery. *Obstet Gynecol* 2000;96(2):295-300.

****Pastore LM**, **Hartmann KE**, Thorp JM, Royce RA, Jackson TP, Savitz DA. Bacterial vaginosis and cervical dilation and effacement at 24-29 weeks gestation. *Am J Perinatol* 2000;17(2):83-8.

****Berkman ND**, Thorpe JM, **Hartmann KE**, et al. Management of preterm labor: Evidence report/technology assessment no. 18. (prepared by Research Triangle Institute under contract No. 290-97-011). AHRQ Publication No. 01-E021. Rockville (MD) Agency for Healthcare Research and Quality. December 2000.

Reid VC, **Hartmann KE, McMahon M, Fry EP. Vaginal preparation with povidone iodine and postcesarean infectious morbidity- a randomized controlled trial. *Obstet Gynecol* 2001;97(1):147-52.

****Hartmann KE**, King VJ. Elective induction of labour: complicating the uncomplicated? *Paed Perinat Epidemiol* 2001;15(2):138-9.

Kuller JA, Meyer WR, Traynor KD, **Hartmann KE. Disposition of sperm donors with resultant abnormal pregnancies. *Hum Reprod* 2001;16(8):1553-5.

****Hartmann KE**, Nanda K, Hall S, Myers E. Technologic advances for evaluation of cervical cytology: is newer better? *Obstet Gynecol Surv* 2001;56(12):765-74.

Thorp JM Jr, **Hartmann KE, Berkman ND, Carey TS, Lohr KN, Gavin NI, Hasselblad V. Antibiotic therapy for the treatment of preterm labor: a review of the evidence. *Am J Obstet Gynecol* 2002;186(3):587-92.

Balu RB, Savitz DA, Ananth CV, **Hartmann KE, Miller WC, Thorp JM, Heine RP. Bacterial vaginosis and vaginal fluid defensins during pregnancy. *Am J Obstet Gynecol* 2002;187(5):1267-71.

Kashuba

Nafziger AN, Bertino JS, Goss-Bley AI, **Kashuba ADM**. Sexual dysfunction on fluvoxamine therapy. *J Clin Psychiatry* 2000;61(1):62-3.

Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, **Kashuba AD. Evaluation of the genetic component of variability in CYP4A4 activity: a repeated drug administration method. *Pharmacogenetics* 2000;10(5):373-88.

Nafziger AN, Bertino JS, Goss-Bley AI, **Kashuba ADM**. Sexual dysfunction and fluvoxamine therapy. *J Clin Psychiatry* 2001;62(2):127-8.

Vernazza PL, **Kashuba ADM, Cohen MS. Biological correlates of sexual transmission of HIV: practical consequences and potential targets for public health. *Reviews in Medical Microbiology* 2001;12:131-42.

Jordan HL, Pereira AS, Cohen MS, **Kashuba AD. Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma. *Antimicrob Agents Chemother* 2001;45(7):2173-6.

Becker S, Fisher A, Flexner C, Gerber JG, Haubrich R, **Kashuba AD, Luber AD, Piscitelli SC. Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus. *J Acquir Immune Defic Syndr* 2001;27(2):210-1.

Streetman DS, **Kashuba AD, Bertino JS Jr, Kulawy R, Rocci ML Jr, Nafziger AN. Use of midazolam urinary metabolic ratios for cytochrome P450 (CYP3A) phenotyping. *Pharmacogenetics* 2001;11(4):349-55.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, **Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. *J Clin Pharmacol* 2002;42(4):376-82.

Hosseinipour M, Cohen MS, Vernazza PL, **Kashuba AD. Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? *Clin Infect Dis* 2002;34(10):1391-5.

Rezk NL, Tidwell RR, **Kashuba AD. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002;774(1):79-88.

**Acosta EP, Gerber JG, and the Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. *AIDS Research and Human Retroviruses* 2002;18(12):825-834.

Chaudry NI, Eron JJ, Naderer OJ, Pereira AS, Wire MB, Fiscus SA, **Kashuba ADM. Effects of formulation and dosing strategy on amprenavir (APV) concentrations in the seminal plasma (SP) of HIV-1 infected males. *Clin Infect Dis* 2002;35:760-2.

Corbett AH, **Kashuba AD. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline. *Curr Opin Investig Drugs* 2002;3(3):384-90.

Corbett AH, Lim ML, **Kashuba AD. Kaletra (lopinavir/ritonavir). *Ann Pharmacother* 2002;36(7-8):1193-203.

Rogers JF, Nafziger AN, **Kashuba AD, Streetman DS, Rocci ML Jr, Choo EF, Wilkinson GR, Bertino JS Jr. Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam: midazolam do not predict midazolam clearance in health subjects. *J Clin Pharmacol* 2002;42(10):1079-82.

Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, Petch L, Cohen MS, **Kashuba AD. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected med. *J Infect Dis* 2002;186(9):1339-43.

Cohen MS, Hosseinipour M, **Kashuba A, Butera S. Use of antiretroviral drugs to prevent sexual transmission of HIV. *Curr Clin Top Infect Dis* 2002;22:214-5.

Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, **Kashuba AD, Schuetz EG, Bertino JS Jr, van den Anker JN, Leeder JS. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. *Clin Pharmacol Ther* 2002;73(3):209-22.

McRae MP, Brouwer KL, **Kashuba AD. Cytokine regulation of P-glycoprotein. *Drug Metab Rev* 2003;35(1):19-33.

Reddy YS, **Kashuba A, Gerber J, Miller V; Roundtable Participants, Forum for Collaborative HIV Research. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. *AIDS Res Hum Retroviruses* 2003;19(3):167-176.

Rezk NL, Tidwell RR, **Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2003;791(1-2):137-47.

Moll

****Moll S**. A low molecular-weight heparin preparation contraindicated during pregnancy. *Am J Obstet Gynecol* 2001;184(5):1046.

Lunin SD, **Moll S. Images in clinical medicine. Suppurative parotitis. *N Engl J Med* 2001;345(9):662.

****Moll S**, Roberts HR. Overview of anticoagulant drugs for the future. *Semin Hematol* 2002;39(3):145-57.

****Moll S**, Ortel TL. Antiphospholipid antibodies. *Arch Intern Med* 2002;162(15):1783-4.

Alukal J, Shrestha R, **Moll S. Images in hematology. Amyloidosis. *Am J Hematol* 2002;71(2):117-8.

Rick ME, **Moll S, Taylor MA, Krizek CM, White GC 2nd, Aronson DL. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. *Thromb Haemost* 2002;88(4):598-604.

Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, **Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounnameaux H, Glynn RJ; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *N Engl J Med* 2003;348(15):1425-34.

****Moll S**, Kudrik FJ, Thomas DB. Catastrophic antiphospholipid antibody syndrome. Am J Hematol 2003;72(4):278-9.

Slotwiner A, Garawacki CP, **Moll S. Castleman's disease. Am J Hematol 2003;73(1):64-5.

****Moll S**. Use of combined CT venography and CT pulmonary arteriography. J Thromb Haemost 2003;1(4):637-9.

Hellman EA, Leslie N, **Moll S**. Knowledge and information satisfaction of individuals with factor V leiden mutation. J Thromb Haemost accepted for Nov 2003; 15 pages.

Stouffer GA, Hirmerova J, **Moll S**, Rubery B, Napoli M, Ohman M, Simpson R. Percutaneous coronary intervention in a patient with ITP, accepted; 10 pages.

Nopachai A, **Moll S**. Images in hematology: Diffuse infiltrative lymphocytosis syndrome- DILS. Am J Hematol, accepted; 2 pages.

Moll S, Huffman J. Images in hematology: Cholesterol emboli associated with warfarin therapy. Am J Hematol, accepted; 2 pages.

Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohre M, Serada M, Sata M, Shimizu H, Yamada K, White GC. Phase I study of a novel human soluble thrombomodulin, ART-123. submitted; 25 pages.

Wang Jennette JC, Mauro MA, **Moll S**. Fibromuscular dysplasia and Parkinson's disease. submitted, 6 pages.

Moll S. Warfarin-induced skin necrosis. Images in Hematology. submitted; 2 pages.

Perrin

Ammerman A, **Perrin EM**, Flower K. Promoting healthy nutrition. Pediatrics. Osborn, DeWitt, Zenel, and First (Eds.). Harcourt Health Services, in press.

Perrin EM, Flower K, Ammerman A. Body mass index charts: useful, yet underused. J Pediatrics, being revised for resubmission.

Perrin EM, Flower K, Ammerman A. Preventing and treating overweight: North Carolina pediatricians' efficacy, barriers, resources, and advocacy. Arch Pediatr Adolesc Med, under review.

Rockhill

Colditz GA, Samplin-Salgado M, Ryan CT, Dart H, Fisher L, Tokuda A, **Rockhill B; Harvard Center for Cancer Prevention. Harvard report on cancer prevention, volume 5: fulfilling the potential for cancer prevention: policy approaches. *Cancer Causes Control* 2002;13(3):199-212.

****Rockhill B**. Proteomic patterns in serum and identification of ovarian cancer. *Lancet* 2002;360(9327):169.

Hall SA, **Rockhill B. Race, poverty, affluence, and breast cancer. *Am J Public Health* 2002;92(10):1559.

Manson J, **Rockhill B, Resnick M, Shore E, Nadelson C, Horner M, Tarbell N, Carr P. Sex differences in career progress and satisfaction in an academic medical center. *J Am Med Womens Assoc* 2002;57(4):194.

****Rockhill B**, Byrne C, Rosner B, Colditz GA. Breast cancer risk prediction with a log- incidence model: evaluation of accuracy. *J Clin Epidemiol* 2003;56:856-61.

Colditz GA, Ryan CT, Dart CH III, Datta G, Fisher L, **Rockhill B**. Quantifying the contribution of risk factors to cancer incidence and the estimated reduction in cancer burden through selected risk factor modification. In Curry SJ, Byers T, Hewitt M, eds. Fulfilling the Potential of Cancer Prevention and Early Detection. Washington, DC: The National Academies Press, 2003.

Kim DJ, **Rockhill B**, Colditz GA. Validation of the Harvard Cancer Risk Index: prediction tool for individual cancer risk. (In print, *J Clin Epidemiol*).

Rockhill B. Smoking and breast cancer. In Surgeon General's Report on Smoking and Health. Rockville, MD: US Department of Health and Human Services, in press 2003.

Taylor

****Taylor JM**, Mack CP, Nolan K, Regan CP, Owens GK, Parsons JT. Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. *Mol Cell Biol* 2001;21(5):1565-72.

Sundberg LJ, Galante LM, Bill HM, Mack CP, **Taylor JM. An endogenous inhibitor of focal adhesion kinase blocks Rac1/JNK but not Ras/ERK-dependent signaling in vascular smooth muscle cells. *J Biol Chem* 2003;278(32):29783-91.

** Have full text copy